Table 1 Demographic characteristics of healthy controls, patients with arthralgia and patients with early RA
From: Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients
Healthy controls (HC) | Patients with arthralgia | Patients with early RA | ||||
|---|---|---|---|---|---|---|
All patients with arthralgia | Arthritis development <1 year (early converters) | Arthritis development >1 year (late converters) | Did not develop arthritis (non-converters) | |||
Individuals (n) | 37 | 113 | 22 | 18 | 73 | 89 |
Median age at inclusion in years (IQR) | 30 (27–41) | 50 (41–57) | 55 (32–65) | 45 (39–57) | 51 (41–58) | 53 (42–60) |
Female (n) (%) | 16 (64) | 86 (76) | 17 (77) | 14 (78) | 55 (75) | 59 (66) |
ACPA positive (n) (%) | N.D. | 69 (61) | 18 (82) | 16 (89) | 35 (48) | 53 (60)a |
RF positive (n) (%) | N.D. | 50 (44) | 12 (55) | 5 (28) | 33 (45) | 49 (55)a |
ACPA and RF positive (n) (%) | N.D. | 29 (26) | 11 (50) | 6 (33) | 12 (16) | 43 (48)a |
Median follow-up time in months (IQR) | N.A. | 26.9 (19.1–42.4) | 8.1 (1.3–12.3) | 22.3 (13.9-41.6) | 36 (25.7–47.9) | N.A. |
Median time to arthritis development in months (IQR) | N.A. | 12.48 (7.4–22.1) | 8.1 (1.3–12.3) | 22.3 (13.9–41.6) | N.A. | N.A. |